Leaders at the University of Minnesota Health and Fairview Health Services, together with researchers from Amgen, have collaborated to create a framework for better predicting the potential for severe infection among chemotherapy patients. Approximately 20% of advanced cancer patients receive treatment that weakens their immune systems and increases the risk of life-threatening infections, in particular, a form of infection known as febrile neutropenia. A good proportion of these complications can be prevented using FDA-approved medications. The problem? There has been no clear standard of care with regard to the prescribing of those medications, with countless patients remaining at undetermined levels of risk. Leaders from all three organizations created a multidisciplinary research team to investigate this issue, extracting data from over 50,000 patients to identify over 8,000 eligible patients at risk for febrile neutropenia and provide granular details into its rates of occurrence. They will share their data analytics journey during this session that is part presentation and part discussion.